Key facts
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G for CELLDEX THERAPEUTICS INC COMMON STOCK (CLDX).
- Disclosed ownership: 5.4%.
- Date of event: 31 Dec 2024.
PRICE T ROWE ASSOCIATES INC /MD/ - 31 Dec 2024 SCHEDULE 13G Report for CELLDEX THERAPEUTICS INC COMMON STOCK (CLDX)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Symbol
- CLDX
- Shares outstanding
- 65,872,889 shares
- Disclosed Ownership
- 3,557,136 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 09:44:09 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Key filing fact
PRICE T ROWE ASSOCIATES INC /MD/ disclosed 5.4% ownership in CELLDEX THERAPEUTICS INC COMMON STOCK (CLDX) on 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 09:44.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 5.4% | 3,557,136 | 3,477,646 | 0 | Ellen York | Vice President |
CIK / CUSIP context first